Polymorphic Variants at NDUFC2, Encoding a Mitochondrial Complex I Subunit, Associate with Cardiac Hypertrophy in Human Hypertension
Overview
Molecular Biology
Authors
Affiliations
Background: A dysfunction of NADH dehydrogenase, the mitochondrial Complex I (CI), associated with the development of left ventricular hypertrophy (LVH) in previous experimental studies. A deficiency of Ndufc2 (subunit of CI) impairs CI activity causing severe mitochondrial dysfunction. The T allele at NDUFC2/rs11237379 variant associates with reduced gene expression and impaired mitochondrial function. The present study tested the association of both NDUFC2/rs11237379 and NDUFC2/rs641836 variants with LVH in hypertensive patients. In vitro studies explored the impact of reduced Ndufc2 expression in isolated cardiomyocytes.
Methods: Two-hundred-forty-six subjects (147 male, 59.7%), with a mean age of 59 ± 15 years, were included for the genetic association analysis. Ndufc2 silencing was performed in both H9c2 and rat primary cardiomyocytes to explore the hypertrophy development and the underlying signaling pathway.
Results: The TT genotype at NDUFC2/rs11237379 associated with significantly reduced gene expression. Multivariate analysis revealed that patients carrying this genotype showed significant differences for septal thickness (p = 0.07), posterior wall thickness (p = 0.008), RWT (p = 0.021), LV mass/BSA (p = 0.03), compared to subjects carrying either CC or CT genotypes. Patients carrying the A allele at NDUFC2/rs641836 showed significant differences for septal thickness (p = 0.017), posterior wall thickness (p = 0.011), LV mass (p = 0.003), LV mass/BSA (p = 0.002) and LV mass/height(p = 0.010) after adjustment for covariates. In-vitro, the Ndufc2 deficiency-dependent mitochondrial dysfunction caused cardiomyocyte hypertrophy, pointing to SIRT3-AMPK-AKT-MnSOD as a major underlying signaling pathway.
Conclusions: We demonstrated for the first time a significant association of NDUFC2 variants with LVH in human hypertension and highlight a key role of Ndufc2 deficiency-dependent CI mitochondrial dysfunction on increased susceptibility to cardiac hypertrophy development.
Mitochondrial complex-1 as a therapeutic target for cardiac diseases.
Rai N, Venugopal H, Rajesh R, Ancha P, Venkatesh S Mol Cell Biochem. 2024; 480(2):869-890.
PMID: 39033212 DOI: 10.1007/s11010-024-05074-1.
Hypertension and Heart Failure: From Pathophysiology to Treatment.
Gallo G, Savoia C Int J Mol Sci. 2024; 25(12).
PMID: 38928371 PMC: 11203528. DOI: 10.3390/ijms25126661.
Gallo G, Rubattu S, Volpe M Int J Mol Sci. 2024; 25(5).
PMID: 38473911 PMC: 10932393. DOI: 10.3390/ijms25052667.
Giriyappagoudar M, Vastrad B, Horakeri R, Vastrad C Biomedicines. 2023; 11(12).
PMID: 38137330 PMC: 10740779. DOI: 10.3390/biomedicines11123109.